UBS analyst Matthew Taylor maintained a Buy rating on InMode (NASDAQ:INMD) Ltd on Wednesday, setting a price target of $47, which is approximately 15.37% above the present share price of $40.74.
Taylor expects InMode Ltd to post earnings per share (EPS) of $0.24 for the fourth quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in InMode, with an average price target of $45.5.
The analysts price targets range from a high of $55 to a low of $38.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $30.77 million and a net profit of $8.11 million. The company's market cap is $1.34 billion.
According to TipRanks.com, UBS analyst Matthew Taylor is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 12.3% and a 70.36% success rate.
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.